A forum for researchers, students and applicants in the field of cyclodextrin technology
The team of Gerhard Wenz (Saarland University, Germany) has published a novel polyrotaxane: hydroxypropyl-β-cyclodextrin(HPBCD):poly(decamethylenephosphate) which has several advantages over HPBCD
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical
CTD Holdings, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need,
The CDNews blog was created in July and after a short period of trial it started in September. During this
According to clinicaltrials.gov, currently, there are 14 cyclodextrin-related clinical trials that in the status of i) Not yet recruiting, ii)
Mallinckrodt Pharmaceuticals recently revealed findings of their completed registration trial for VTS-270 (Hydroxypropyl Betadex- HPBCD), a development product to treat
A paper has just come out in Macromolecular Rapid Communications highlighting the potential benefits of cyclodextrin-based macromolecular systems as cholesterol-mopping
Cockayne syndrome is a hereditary form of premature aging caused by a gene mutation. The disease affects more organs including
If you are following advances in the re-discovery of cyclodextrins as APIs, there is quite a race among the candidates
Clearly, understanding the mechanism of action for cyclodextrins and consequently finding the most appropriate canditate for the treatment of Niemann
